Read + Write + Report
Home | Start a blog | About Orble | FAQ | Blogs | Writers | Paid | My Orble | Login

CELLESTIS: PLAYING THE BALL, NOT THE MAN, PAYS OFF

May 30th 2011 00:05

Biotech Daily

Monday April 4, 2011

Daily news on ASX-listed biotechnology companies

subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au


MARC SINATRA’S BIOGUIDE BRIEF: CELLESTIS


Well, there seems to be little doubt that foreign companies think Australian biotech is all right – and cheap, even given the strength of the Australian dollar.

First, Cephalon took a slice of Mesoblast and a slice of Chemgenex. They then came back for the rest of the Chemgenex pie. Now, Germany company Qiagen has decided to just skip the slice and go for the whole Cellestis pie.

Cellestis has been one of Australian biotechnology’s quiet achievers, having toiled through two iterations of its Quantiferon test for tuberculosis before nailing it with the third “in-tube” version.

The $3.55 offer per share seems okay, but is not great.

There are those who speculate Cellestis will eventually reach a tipping point in sales in the US and once this point is reached, it is thought sales will rapidly escalate as the majority of places testing for TB switch en-masse to Quantiferon.

If you are a believer in this scenario, than $3.55 isn’t a good offer at all. If you aren’t a believer, than the offer price is pretty good. Will we see a rival bidder enter the fray? It seems possible.

The Quantiferon tests would be quite a good fit with the world’s largest diagnostics company, Quest Diagnostics. With its reach, Quest could probably get Quantiferon sales to that “tipping point” much more quickly than Qiagen.

Quantiferon would also fit with several other large diagnostic companies.

At this stage, though, a higher offer is mere speculation. What is certain is that Australian biotechnology companies are in demand on the world stage and this bodes well for the future of the industry.

Marc Sinatra’s Bioguide



subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au





9
Vote
Add To: del.icio.us Digg Furl Spurl.net StumbleUpon Yahoo


   
subscribe to this blog 


   

   




Add A Comment

To create a fully formatted comment please click here.


CLICK HERE TO LOGIN | CLICK HERE TO REGISTER

Name or Orble Tag
Home Page (optional)
Comments
Bold Italic Underline Strikethrough Separator Left Center Right Separator Quote Insert Link Insert Email
Notify me of replies
Your Email Address
(optional)
(required for reply notification)
Submit
More Posts
2 Posts
1 Posts
2 Posts
546 Posts dating from August 2006
Email Subscription
Receive e-mail notifications of new posts on this blog:
0

Biotech Daily Editor's Blogs

I have no other blogs :(
Copyright © 2012 On Topic Media PTY LTD. All Rights Reserved. Design by Vimu.com.
On Topic Media ZPages: Sydney |  Melbourne |  Brisbane |  London |  Birmingham |  Leeds     [ Advertise ] [ Contact Us ] [ Privacy Policy ]